Immune Therapeutics, Inc., The Jack Brewer Foundation, and CareMed Pharmaceutical Services Donation
ORLANDO, FL. and MALAWI March 11, 2015-- Immune Therapeutics, Inc. (OTC:BB IMUN), The Jack Brewer Foundation (JBF Worldwide), and CareMed Pharmaceutical Services are pleased to announce a successful Donation Ceremony that took place in Malawi on February 5th, 2015.
The Ceremony was held to highlight the delivery of six Wallach LL100 Cryotherapy devices to Queen Elizabeth Central Hospital in Blantyre, Malawi that took place on January 28th, 2015. The delivery marked the initial stage of a first-of-its-kind treatment opportunity for this region.
“We are very pleased that our collective efforts have resulted in such rapid deployment of this equipment,” noted Noreen Griffin, Chief Executive Officer of Immune Therapeutics. “Given that there is essentially no oncology care available to women in Malawi, each of these cryotherapy devices can potentially save the lives of thousands of women each year.”
The Wallach LL100 Cryosurgical Systems remove cervical precancerous lesions and are a treatment that is advocated to achieve a reduction in Invasive Cervical Cancer (ICC) mortality in developing countries. The cryosurgical procedure has safely been performed by primary care professionals, nurses, and other non-physicians in lower level facilities. The Wallach LL100 system is relatively inexpensive and does not require electricity. Thus, this approach is very practical for low-resource settings.
The goal of the donation of this medical equipment is to provide early treatment intervention. Then, any further treatment can be handled by trained nurses and physicians assistants throughout Malawi. In addition, the program anticipates delivering Immune Therapeutics’ Lodonal immunotherapy drug, a proven immunmodulator that activates the immune system against many opportunistic infections and diseases, including cancer and HIV/AIDS. The Lodonal immunotherapy drug would serve as a treatment to combat the rise in cases of cervical cancer throughout the country.
The Donation Ceremony was attended by Ministry of Health Officials, College of Medicine Senior Staff, Kamuzu College of Nursing, Cancer Association of Malawi, and representatives of the Association of Obstetricians and Gynecologists of Malawi.
“The impact of these cryosurgical guns will be unimaginable to the communities we will be utilizing them in,” commented Dr. Frank Taulo, Coordinator of the Donation Ceremony. “As a country [Malawi], we have not yet been able to secure this technology for all the screening centers, but this will serve as a leap forward to a place where we will be able to.”
Dr. Frank Taulo and Dr. Leo Masamba will be conducting two case studies using the new devices in the surrounding communities to provide more insight and information on how the system’s pre-screening and early intervention will prevent death from cervical cancer.
This donation was provided by Immune Therapeutics, Inc., The Jack Brewer Foundation and CareMed Pharmaceutical Services. Anyone can participate in supporting this ongoing program by providing donations as small as $1.00. For more information about the Malawi health care initiative and trials and to donate, please visit:
https://reelcause.com/jbfworldwidegaprogram/2015/01/immune-therapeutics-healthcare-initiative/
###
About Immune Therapeutics, Inc.
We are a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
Our proprietary technology, therapies and patents include the treatment of a wide range of cancers. Our most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and our Low Dose Naltrexone product (LDN) or Lodonal™, which have been shown to stimulate the immune system even in patients with advanced cancer.
Even though management considers any condition that results in altered-immune response a target for investigation, we will most likely pursue additional investigations for MENK and LDN as valuable candidates in the treatment of autoimmune states such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy. (http://www.immunetherapeutics.com)
About The Jack Brewer Foundation
Jack Brewer, five-year National Football League (NFL) veteran and founder/CEO of The Brewer Group, Inc., established The Jack Brewer Foundation (JBF Worldwide) to empower women and children living in impoverished and underdeveloped communities by enabling food security; promoting access to education and cultural exchanges; assisting in medical aid and disaster relief; and building peace. JBF Worldwide uses sport as a catalyst to provide resources and opportunities to the world’s most underserved populations and actively works to “Empower From Within.” For more information about The Jack Brewer Foundation, please visit www.jbfworldwide.org or follow them on Facebook, Twitter, Instagram and Pinterest.
About CareMed Pharmaceutical Services
CareMed Pharmaceutical Services is an industry leader within the Specialty Pharmacy field. Their commitment to high-quality and efficient patient care is unparalleled. The company maintains dual accreditations from ACHC and URAC. CareMed offers 24/7/365 prescription services, remote consultations with certified pharmacists and nurses, comprehensive patient assistance programs, and disease-specific care management services. Connect with CareMed online at http://www.caremedps.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release and the statements of our management, representatives and partners and our subsidiaries related thereto include various “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent our expectations or beliefs concerning future events. Statements containing expressions such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” used in this press releases and in our filings with the Securities and Exchange Commission as well as Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve assumptions and significant risks and uncertainties. Readers are cautioned that certain important factors may affect our actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release, and thus readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. Actual results may differ significantly from those set forth in the forward-looking statements. We undertake no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.